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Glioblastomamultiforme (GBM) is themost aggressive primary brain tumor with a median survival of 12 to 15months
after diagnosis. Acquired chemoresistance, high systemic toxicity, and low penetration of the blood brain barrier by
many anticancer drugs contribute to the failure of anti-GBM therapies. To circumvent some of these obstacles, we
tested a novel prodrug approach to evaluate anti-GBM efficacy by utilizing serum albumin-binding doxorubicin (Doxo),
aldoxorubicin (Aldoxo),which is less toxic, is released fromalbumin in an acidic environment and accumulates in tumor
tissues. A human GBM cell line that expresses a luciferase reporter (U87-luc) was stereotactically injected into the left
striatum of the brain of immunodeficient mice. Following initial tumor growth for 12 days, mice were injected once a
week in the tail-vein with Aldoxo [24 mg/kg or 18 mg/kg of doxorubicin equivalents—3/4 maximum tolerated dose
(MTD)], Doxo [6 mg/kg (3/4 MTD)], or vehicle. Aldoxo-treated mice demonstrated significantly slower growth of the
tumor when compared to vehicle-treated or Doxo-treated mice. Five out of eight Aldoxo-treated mice remained
alive more than 60 days with a median survival of 62 days, while the median survival of vehicle- and Doxo-treated
mice was only 26 days. Importantly, Aldoxo-treated mice exhibited high levels of Doxo within the tumor tissue,
accompanied by low tumor cell proliferation (Ki67) and abundant intratumoral programmed cell death (cleaved
caspase-3). Effective accumulation of Aldoxo in brain tumor tissues but not normal brain, its anti-tumor efficacy,
and low toxicity, provide a strong rationale for evaluating this novel drug conjugate as a treatment for patients
afflicted with GBM.
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Glioblastoma multiforme (GBM) is the most aggressive primary
neoplasm of the central nervous system (CNS) accounting for
approximately 60% of all primary brain tumors with 12,500 new cases
diagnosed in the US annually [1,2]. Standard of care for newly
diagnosed GBM remains a multimodal regimen consisting of surgical
resection with concomitant daily temozolomide (TMZ) and radiation
therapy, followed by adjuvant TMZ [3]. Nevertheless, the increase in
median survival is only 2.5 months compared with individuals treated
with radiotherapy alone [3,4]. Additionally, acquired chemoresistance
is a major problem with this therapy. Essentially all patients develop
recurrent or progressive disease after the initial therapy showing no
response to repeated challenges with TMZ [5]. Currently, bevacizu-
mab, a monoclonal antibody targeting vascular endothelial growth
factor, remains the only Food and Drug Administration approved drug
as a single-agent for the treatment of patients with recurrent or
progressive GBMs. Despite the encouraging beneficial effects seen in a
number of clinical trials, this anti-angiogenic therapy has not produced
the therapeutic responses initially envisioned [6,7]. Emerging evidence
from both the clinical and laboratory studies suggests that GBM
rapidly adapts to anti-vascular endothelial growth factor therapy
leading to rapid tumor progression, and the patients who progress
following bevacizumab treatment, poorly respond to bevacizumab-
based combinations [7,8]. Thus, considering the overall failure of these
approaches in the treatment of GBM, there is an urgent need for more
effective therapies to achieve improved outcomes in newly diagnosed
and recurrent GBM patients.
Chemotherapy is of limited use as treatment for GBM either
because of acute systemic toxicities, or poor penetration of the blood-
brain barrier (BBB) [9,10]. Doxorubicin (Doxo), an anthracycline
antibiotic, is a highly effective therapeutic agent for the treatment of
many malignant tumors, however, its dose-related systemic toxicity
and lack of penetration through the BBB limit its use in the treatment
of intracranial tumors [11,12]. Several different formulations of
doxorubicin have been developed, including pegylated liposomal
doxorubicin (Doxil) [13–15]. However, none of these agents showed
activity in preclinical studies or in phase I/II clinical trials as a
treatment option for brain tumors.
Aldoxorubicin (Aldoxo; CytRx Corporation), formerly known as
INNO-206, is a (6-maleimidocaproyl) hydrazone conjugate of
doxorubicin (Doxo), which binds rapidly and selectively to the
Cysteine-34 position of circulating serum albumin after intrave-
nous administration, and releases Doxo selectively at tumor sites
because of the low pH of the tumor environment [16]. Once
released intracellularly, the Doxo intercalates DNA, inhibits DNA
synthesis, and induces apoptosis. Preclinically, Aldoxo has
demonstrated superior anti-tumor activity relative to Doxo in
tumor xenograft mouse models for breast, ovarian, pancreatic, and
lung cancers [17,18]. More recently, Aldoxo has demonstrated
activity against multiple myeloma cells in vitro and in vivo, as well
as enhancement of the anti-tumor effect of bortezomib (velcade), a
drug approved for the treatment of relapsed multiple myeloma
[19]. A phase 1 study of Aldoxo demonstrated its safety and
favorable clinical responses in a variety of tumor types [20]. Because
of these encouraging results we examined the preclinical efficacy of
Aldoxo against GBM using a mouse intracranial GBM model in
which progression of the tumor growth, CNS invasion, as well as
penetration of the drug into tumor and normal brain could be
studied in a quantitative fashion.Materials and Methods
Intracranial Implantation of U87-luc Glioma Cells in Mice
A human GBM U87MG subline, U87-luc stably integrated with a
luciferase reporter gene [21], kindly provided by Dr. Daniel A. Vallera
[22], was used for establishing intracranial xenograft GBM tumors.
Female athymic nude mice, 6 to 8 weeks of age (Harlan Laboratories),
were anesthetized with a ketamine/xylazine cocktail solution. Animals
were secured in a Harvard Apparatus stereotaxic head frame, a 1-cm
midline scalp incision was made, and 5 × 105 cells in 5 μl serum-free
DMEM were injected into the left striatum (coordinates: 2.5 mm
lateral and 0.5 mm posterior to the bregma) through a burr hole in the
skull using a 10-μl Hamilton syringe to deliver tumor cells to a 3.5-
mm intraparenchymal depth. The burr hole in the skull was sealed
with bone wax and the incision closed using Dermabond. Tumor
growth was monitored and measured via bioluminescence imaging
in vivo. All experiments were performed in accordance with the
Institutional Animal Care and Use Committee guidelines.
Drug Treatment of Mice
Aldoxorubicin (Aldoxo; CytRx Corporation, Los Angeles, CA) and
Doxo (Sigma-Aldrich, cat # 44583) were prepared on each day of
injection in sterile vehicle (10 mM of sodium phosphate, 5% of D-(+)-
glucose, pH 6.4) at a concentration of 10 mg/3 ml and 3 mg/3 ml,
respectively. The dosing formulationswere stored at 4°C before injection
and were injected within 1 hour of formulation. Both drugs were
administered intravenously in a volume of 0.15ml to achieve 75%of the
maximum tolerated Aldoxo dose of 32 mg/kg per injection and Doxo
dose of 8 mg/kg per injection for a 20-g mouse. The study consisted of 8
vehicle-treated control mice (group C), 8 Doxo-treated mice (group
D), and 8 Aldoxo-treated mice (group A). Treatment was initiated
12 days after intracranial implantation of GBM cells. Vehicle or
Aldoxo was administered for a total of six injections (i.e., 12, 19, 26,
42, 50, and 56 days after cell implantation). Doxo was administered
intravenously for a total of only two injections (i.e., 12 and 19 days
after cell implantation), because seven of the eight mice in this group
died before the third injection.
In Vivo Imaging of Intracranial Tumors
Intracranial tumor growth was quantified by biophotonic imaging
using a Xenogen IVIS 200 system (Xenogen, Palo Alto, CA). Mice
were administered a 100-μl intraperitoneal injection of 30-mg/ml D-
luciferin (PerkinElmer) suspended in DPBS (Gibco) 10 minutes
before imaging as a substrate for the luciferase enzyme. Prior to
imaging, anesthesia was induced with isoflurane gas by placing mice
in the chamber of an XGI-8 vaporizer, and sustained by inhalation via
nose cones inside the imaging chamber. Images were captured and
quantified with Living Image 4.1 software based on equivalent
regions of interest over the head. Image intensities were expressed as
photons per sec/cm2 per steradian.
Neurotoxicity and Morbidity Assessments
Neurotoxicity was assessed by signs of motor disturbances and/or
imbalance, and morbidity by rapid weight loss, impaired mobility,
decreased food intake, and signs of lethargy.
High-Performance Liquid Chromatography (HPLC) System
and Conditions
The HPLC system used was an Agilent 1100 Series (Wilmington,
DE) equipped with a scanning fluorescent detector with excitation
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Agilent Chemstation software was used for data acquisition.
Separation was achieved on a Waters Spherisorb ODS2 column
(4 mm × 250 mm, 5 μm) fitted with a guard cartridge (BDS-
Hypersil-C18, 5 μM). Elution was performed with mobile phase
comprised of 65% 50 mM monosodium phosphate, pH 2.2, and
35% acetonitrile. A constant flow rate of 1.25 ml/min was used for
the separation. The column was set to 28°C and the injection volume
was 25 μl.
Doxo, Aldoxo, and the internal standard daunorubicin (Sigma-
Aldrich, cat # 30450) demonstrated average retention times of 4.06,
4.39, and 6.52 min, respectively, and were sufficiently resolved under
the applied assay conditions. In the organ samples analyzed, Aldoxo
eluted with the retention time of Doxo. No interfering peaks were
observed under the chromatography conditions used.
Sample preparation. For quantification of Aldoxo in brain and
brain tumors, Aldoxo, 24 mg/kg per injection (18 mg/kg Doxo
equivalents; 75% of the maximum tolerated dose (MTD)), was
administered to intracranial GBM tumor-bearing and non-tumor-
bearing mice via tail vein injection. After 6 and 24 hours of Aldoxo
injection, mice (n = 3 per time point) were euthanized by CO2
inhalation, brains were harvested and tumors were resected. The
harvested brain and tumor tissues were stored at −80°C until analysis.
Frozen samples were thawed at room temperature and homoge-
nized in sterile saline using a PowerGen Model 125 homogenizer
(Fisher Scientific) to obtain final tissue concentrations (w/v) of
150 mg/ml. Perchloric acid (35%, v/v) was then added to a 20-μl
aliquot followed by 25 μl of mobile phase. The samples were vortexed
followed by centrifugation at 10,000× g for 10 minutes and 25 μl of
the supernatant was applied to the HPLC column. In the tissue
samples analyzed, Aldoxo eluted with the retention time of Doxo.
Immunohistofluorescence
For histologic analysis, brain tissues from control and drug-treated
tumor-bearing mice were harvested, snap frozen in optimal cutting
temperature embedding medium and stored at −80°C. Cryostat
sections were placed on slides and fixed in zinc-buffered formalin.
Slides were blocked with 5% goat serum in 1% BSA followed by
overnight incubation with primary antibodies against CD31
(102402, Biolegend, San Diego, CA), Ki-67 (ab156956, Abcam,
Cambridge, MA), Vimentin (ab92547, Abcam), and cleaved-
Caspase-3 (CP229B, Biocare Medical). Slides were then incubated
with secondary antibodies conjugated to Alexa Fluor 488 or 635,
washed and treated with 4′,6-diamidino-2-phenylindole as a nuclear
counterstain. The detection fluorophores used were limited to those
around the inherent fluorescence spectra of Doxo (λex = 480 nm,
λem = 550 to 590 nm) [23] to avoid bleed-through and enable co-
detection of the drug with respect to certain antigens. Epifluorescence
photomicrographs were captured at 100× and 400× magnification
using an FV1000 confocal microscope (Olympus of America, Center
Valley, PA) equipped with multi-Argon, 405, 559, and 635 diodes.
Quantitative analysis was performed with Slidebook 5 software
(Intelligent Imaging Innovations, Denver, CO).
Aldoxo/Doxo Detection in Brain Tumors
Tumor-bearing mice were given intravenous injections of Aldoxo
or Doxo as described above. Mice were euthanized 24 hours following
the last injection. Brains were harvested and imaged using an MVX10
stereomicroscope (Olympus of America) equipped for brightfield andepifluorescence with filters encompassing Doxo-specific wavelengths
to visualize drug accumulation.
Statistical Analysis
Analyses were carried out in SAS 9.3 (SAS Institute, Inc., Cary,
NC). Radiance data for experimental groups (Figure 4A) were
assessed by the Kruskal-Wallis test followed by Dunn's multiple
comparisons. Kaplan-Meier estimates of group survival functions
were obtained and pairwise comparisons were performed by exact log-
rank tests [24]. The median survival time for each experimental group
and its 95% confidence interval was also estimated. P ≤ 0.05 was
considered statistically significant.
Results
Aldoxo Inhibits Intracranial Growth of GBM Tumors
To evaluate anti-GBM efficacy of Aldoxo, we injected 5 × 105
U87-luc cells (human GBMU87MG cells stably expressing luciferase
reporter) intracranially into immunodeficient mice, and the tumor
cells were allowed to grow for 12 days without treatment.
Subsequently, all tumor-bearing mice were randomly divided in to
three groups (n = 8) and each mouse received a series of intravenous
injections: Group A: Aldoxo [24 mg/kg per injection, 3/4 MTD];
Group D: Doxo [6 mg/kg per injection (3/4 MTD)]; and Group C:
vehicle, (10 mM sodium phosphate, 5% D-(+)-glucose, pH 6.4); the
injections were repeated once a week for the duration of the
experiment (up to 60 days). Tumor growth was monitored weekly
using in vivo quantitative bioluminescence (Xenogen IVIS-200). The
results in Figure 1 show individual bioluminescence images of the
brain tumors from the three experimental groups (A, Aldoxo; D,
Doxo; and C, vehicle), which were taken at 8, 16, 22, 27, 34, and 41
days following the intracranial implantation of U87-luc cells. At the
8-day time point, most of the mice showed development of small
brain tumors; three mice (A17, D12, and C4) exhibited tumors that
were relatively larger, and two mice (D16 and C7) had no detectable
tumors. At the 16-day time point, all 24 mice had intracranial tumors
which varied in size, although Group A appeared to exhibit smaller
tumors than the other groups. At the 22-day time point, tumor
growth in mice from Groups C and D appeared to be highly
aggressive, with 3 mice dead in group C and 2 in group D as a result
of large brain tumors. All mice in group A were alive and
demonstrated significantly smaller tumors compared with the tumors
in groups C and D. At the 27-day time point, 13 mice from groups C
and D were dead and the remaining three (C1, C3, D14) had very
large tumors. All mice in group A remained alive and had tumors
which were significantly smaller in comparison to tumors in the
control and Doxo-treated mice. By the 34-day time point, all mice
from groups D and C were deceased, whereas all mice in group A were
still alive with minimal tumor progression. At Day 41, one mouse
from Group A died, while the remaining mice did demonstrate
increased but slow tumor progression.
Quantification of changes in the tumor size over time, are shown in
Figure 2. The tumor sizes were calculated according to luminescence
intensity expressed as radiance (photons per sec/cm2 per steradian) × 107.
During the first 16 days following the initial injection of the drugs all
intracranial tumors increased in size without any significant differences
between the control, Doxo-treated, and Aldoxo-treated mice. The first
significant difference was observed at day 22, when the tumors in Aldoxo-
treated mice were ~4-fold (P = 0.0054) and ~3-fold (P = 0.052) smaller
when compared to the tumors in the control and Doxo-treated mice,
Figure 1. Biophotonic measurement of orthotopic GBM xenografts in vivo provide evidence that Aldoxo has a significant anti-tumor effect
when compared to Doxo-treated or untreated tumor-bearingmice. Female athymic nudemice were intracranially infusedwith 5× 105 firefly
luciferase-labeled U87MG (U87-luc) glioma cell. Mice were divided into control (C), Doxo (D)-, and Aldoxo (A)-treated groups with n = 8 per
group. After 12days, groupsC (1-8), D (9-16), andA (17-24)were injectedwith drug vehicle, 120 μg per injection ofDoxo (basedon a 20 g body
weight), or 480 μg per injection of Aldoxo, respectively. Injection with Doxowas repeated after 19 days andwith Aldoxo after 19 and 26 days.
Bioluminescence imaging of brain tumors was performed after 8, 16, 22, 27, 34, and 41 days of tumor cell implantation and is shown as a
function of total radiance in photons per sec/cm2 per steradian. Tumor burden is demonstrated by a colorimetric scale where red represents
the highest range of radiance values which translates to tumor burden. Red daggers indicate death of the animal.
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control animals (P = 0.035) and 8-fold for Doxo-treated animals (p =
0.37, not significant because of the large standard deviation) by day 27. At
this time point, all the eight mice in the Aldoxo group were still alive,
whereas twomice in theDoxo group and onemouse in the control group
died during the imaging procedure. Tumors in the dead mice were
measured postmortem. After 34 days, when all Doxo-treated and vehicle-
treated mice were deceased, the remaining Aldoxo-treated micedemonstrated a slow increase in tumor size. The experiment was
terminated at the day 62, when five Aldoxomicewere still alive but started
to appear moribund.
Effects of Aldoxo Treatment on the Survival Time of Mice
Bearing Intracranial U87-luc GBM Tumors
Whereas all mice in the vehicle-treated (control) and Doxo groups
died within 30 days of tumor cell implantation, five of the Aldoxo-
Figure 2. Tumor-bearing mice treated with Aldoxo display
decreased tumorigenesis and increased survival when compared
to untreated and Doxo-treated groups. Radiance values from
identical regions of interest of untreated, Doxo-, and Aldoxo-treated
tumor-bearing mice from Figure 1 were averaged and compared at
selected time points following intracranial implantation of U87-luc
cells. *Aldoxo treatment vs. control after 22 days (P = 0.005) and
28 days (P = 0.035) (t test).
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isoflurane anesthesia used during imaging and two euthanized because
of the moribund condition. The results shown in Figure 3, demonstrate
a highly significant improvement in the survival time in Aldoxo-treated
mice as compared with control or Doxo-treated mice (P = 0.0002 for
each comparison). Themedian survival times (95% confidence interval)
of mice in the control, Doxo-treated and Aldoxo-treated groups were
25.5 (20, 28), 26.0 (19, 27) and 62.0 (34, 62) days, respectively. Thus,
intravenous Aldoxo treatment increased the median survival time by
36 days, which represents an extension in the life span of mice bearingFigure 3. Tumor bearing mice experience significantly longer
survival following treatment with Aldoxo. Kaplan-Meier curves are
compared between mice bearing U87-luc tumors treated with
vehicle, Doxo, and Aldoxo. Doxo and Aldoxo were administered at
75%MTD as described inMethods. Statistical analysis of n = 8 per
group reveals significantly longer survival (P = 0.0002) of mice
treated with Aldoxo when compared against either vehicle or Doxo-
treated mice.intracranial GBM by 138% [(36/26)*100]. The average difference in
the median survival time between the control and Doxo-treated mice
was only 0.5 day (P = 0.715).
Accumulation of Aldoxo and Doxo in the Brain and Brain
Tumor Tissue Following Intravenous Drug Delivery
HPLC was used to detect Aldoxo content (elutes with the retention
time of Doxo) in the intact brain and the brain tumor tissue following
intravenous injection of Aldoxo (Figure 4A). At the 6-hour time point
following a single tail-vain delivery of Aldoxo (24 mg/kg per
injection), the average concentration of the drug in the brain tumor
tissue was over four-fold greater than in the adjacent intact brain
tissue. At the 24-hour time point, the concentration of Aldoxo
declined significantly in both brain and brain tumor tissue, however it
was still at least two-fold higher in the tumor. Interestingly, Aldoxo
was undetectable in the brain tissues of non-tumor-bearing mice,
suggesting that Aldoxo detection in the brain tissues of tumor-bearing
mice may be the result of disrupted blood brain barrier or other
structural alterations in the brain tissue surrounding the tumor.Figure 4. High accumulation of Doxo is specific to orthotopic GBM
xenograft tissue but only during treatment with Aldoxo. (A) Tumor
and surrounding brain tissue from Aldoxo-injected mice were
selectively harvested at 6 and 24 hours post-treatment and
processed for HPLC. Data represent average values of Aldoxo
(elutes with the retention time of Doxo) concentration (ng/mg) with
statistical significance of differences between Aldoxo-treated non
tumor-bearing (control), and tumor-bearing mice. (B) Whole brains
harvested from Aldoxo- and Doxo-treated mice were photomicro-
graphed by epifluorescence stereomicroscopy to visualize the
extent of Doxo-specific fluorescence around the stereotactic
infusion site of U87MG cells (yellow circle).
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natural fluorescence of Doxo (excitation 480 nm, emission 500 to
590 nm). The brains were harvested 24 hours following the tail-vein
injection of Aldoxo and Doxo, and were imaged using an
epifluorescence stereomicroscope. As shown in Figure 4B, the
Aldoxo-treated mice demonstrated a strong red fluorescence at the
injection site of the tumor cells (yellow circle), and the expansion of
the fluorescence towards the occipital region of the brain, which in
this particular case corresponded to the area of the tumor growth. In
contrast, we did not observe any red fluorescence in the brain or in
the brain tumor tissues of Doxo-treated mice, further supporting
the unique ability of Aldoxo to reach intracranial GBM tissue, andFigure 5. Doxo fluorescence is highly localized to cells in orthotopi
Aldoxo. (A-C) Frozen sections of brain tissue housing tumor xenograf
(green) to label tumor-specific area and vasculature, respectively, a
confocal imaging at 100× magnification (100-μm bar). The innate red
twomarkers and this channel was extracted in (A′-C′) grayscale for bet
within glioblastoma (gbm) and normal (n) tissue. (D) Subsampling o
rectangle) at 400× shows localization of Doxo to the cytosol and nuc
tissue (50-μmbar). (E, F) The effect of Aldoxo on tumor content and va
over total tumor area.having only a minimal effect on the surrounding brain tissue. To
evaluate if Doxo-specific fluorescence seen macroscopically
(Figure 4B), results also in the selective incorporation of the drug
into the tumor cells, we examined cryosections of the brain tissue
from the control, Doxo-treated and Aldoxo-treated mice. The
results in Figure 5 demonstrate an abundant accumulation of Doxo
(red fluorescence) in the area occupied by the brain tumor from the
Aldoxo-treated mice (panels C-C′ and D). The tumor cells from the
control and Doxo-treated mice were completely negative (panels A-
A′ and B-B′). The image depicted in panel D is a higher
magnification of the margin between the tumor and unaffected
brain tissue (rectangle from panel C), which clearly indicates thatc U87-luc xenografts but only in tumor-bearing mice treated with
ts were co-immunostained against Vimentin (VIM, blue) and CD31
nd counterstained with nuclear 4′,6-diamidino-2-phenylindole for
fluorescence of Doxo was also co-detected with respect to these
ter demonstration of the localization of Doxo between samples and
f a region of interest from the Aldoxo treated tumor in C (yellow
lei of VIM+ U87-luc cells with minimal expression in adjacent brain
scular area was assessed by quantitation of CD31+ and VIM+ cells
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intracellular Doxo-specific red fluorescence.
In addition, the same sections were immunolabeled using anti-
CD31 (green) and anti-Vimentin (blue) antibodies to evaluate
possible effects of the Aldoxo-treatment on the tumor vascularization
and the expression of vimentin, a pro-invasive intermediate filament
protein, respectively. It is noteworthy that, we did not observe the
expected reduction in the vascularization (CD31-positive immuno-
labeling) of the tumors from Aldoxo-treated mice that were strongly
positive for Doxo red fluorescence. Although not significant (P =
0.3964), the CD31 immuno-positivity was actually higher in these
tumors (panel E). Aldoxo-treatment was associated with a slight
reduction in the number of vimentin-positive tumor cells, although
not significant (P = 0.099) (panel F).
Effect of Aldoxorubicin Treatment on Tumor Cell Proliferation
and Apoptosis
To assess the effects of the Aldoxo-treatment on tumor cell
proliferation and apoptosis, cryosections of the intracranial tumor
tissue were co-immunolabeled with anti-Ki67 and anti-cleaved
Caspase-3 antibodies, respectively. The results in Figure 6, A and B
demonstrate that in comparison to the control vehicle-treated mice,
the Aldoxo-treatment reduced the number of Ki-67 positive tumor
cells over 3-fold (P = 0.018) per tumor area (Figure 6C). Co-detection
of apoptosis with anti-cleaved caspase-3 within the same section
demonstrated a highly significant increase (P = 0.0005) in pro-
apoptotic signaling in the Aldoxo-treated mice compared to tumors
from the control mice (Figure 6, D–F). This observation indicates
that cells within the tumor appear to undergo apoptosis following
intravenous delivery of Aldoxo. Importantly, we did not observeFigure 6. Treatment with Aldoxo decreases the proliferation index
Immunodetection and quantitation of the proliferation marker (A-C,
differences in the survival dynamics of non-treated (NT) and Aldoxo-tprogrammed cell death in the brain areas adjacent to the tumor tissue
(not shown), supporting that Aldoxo treatment does not have an
adverse effect on the normal cells even at the tumor margins.
Discussion
GBM is the most common and lethal CNS malignancy, accounting
for nearly 60% of the primary brain tumors [1]. Although aggressive
surgery combined with radiation and temozolomide chemotherapy
prolong survival of GBM patients, these tumors frequently acquire
chemoresistance. A number of therapeutic strategies have been
evaluated over the years in patients with recurrent or progressive
disease, but no consistent survival benefit has been observed. Thus,
the development of new more effective treatments to achieve durable
outcomes remains a major therapeutic challenge.
To be effective, a cytotoxic drug must reach tumor cells at
therapeutic concentrations. Although, Doxo is a highly efficient
chemotherapeutic agent for the treatment of a wide variety of
systemic cancers, its clinical application is limited in the treatment of
brain tumors because of its inability to penetrate the BBB [12,25].
Thus, in recent years, efforts have been made to develop novel
compositions of Doxo that exhibit reduced toxicity and improved
therapeutic efficacy (cf. pegylated liposomal Doxo, Doxil) [13–15].
Although these new approaches improve the half-life of the drug and
reduce some of its systemic toxicities they do not overcome the
problem of effective penetration and release of the active drug in brain
tumor tissue. In the present study, we analyzed the antitumor activity
of a conjugated Doxo that binds covalently to circulating albumin
(Aldoxo) and compared its efficacy to free Doxo in immunodeficient
mice bearing intracranial human U87-luc GBM tumors. Aldoxo is a
novel drug-conjugate of Doxo in which Doxo is derivatized at its C-of tumor cells and triggers increased apoptosis in xenografts.
G, H) Ki-67 and effector of apoptosis (D-F, G, H) reveal significant
reated tumor tissue. Calibration bar = 50 μm.
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maleimidocaproic acid hydrazide. This modification allows Aldoxo
to bind selectively to the cysteine-34 residue of the circulating serum
albumin after intravenous administration [16,17] with release of
Doxo either extracellularly in the slightly acidic environment present
at the tumor site or intracellularly in the acidic endosomal or
lysosomal compartments of the tumor cells [17,26].
Our results demonstrate that in comparison to free Doxo, which
was ineffective against intracranial GBM, Aldoxo had a pronounced
antitumor activity in our animal model. Aldoxo-treated mice
demonstrate significantly slower growth of the tumor and prolonged
the survival time of the tumor bearing mice by more than 100% as
compared to vehicle-treated and Doxo-treated mice. Importantly,
Aldoxo-treated mice demonstrate accumulation of Aldoxo exclusively
at the brain tumor sites suggesting its effective penetration through
the blood brain-tumor barrier but not through the BBB. This highly
selective accumulation of Aldoxo inside the brain tumor tissue and its
low penetration in to the tumor-free brain could be very important to
reduce any potential neurotoxicity due to Doxo.
We further evaluated how intravenous Aldoxo-treatment affects
growth and survival of the tumor cells inside the intracranial tumor
tissue. Our immunohistofluorescent data using antibodies specific to
the cleaved (active) form of caspase-3 and to Ki-67, a cell proliferation
marker clearly demonstrated abundant apoptosis and a very low
tumor cell proliferation. However, in spite of these very positive
effects of Aldoxo against the tumor cells in vivo, we did not observe
expected changes in the immunolabeling for the endothelial marker
CD31 suggesting that intratumoral endothelial cell proliferation and
tumor vascularization is not affected by the drug. It is possible that the
environment inside the newly formed vasculature, different than
tumor tissue, is not acidic enough to cleavage the drug from its carrier,
albumin. Therefore, it would be important to test if a vascular-
disruptive agent such as bevacizumab [27] could be used in
combination with Aldoxo to target simultaneously tumor cells and
neovascularization in GBM.
The median lethal dose of Aldoxo in CD-1 mice is established to be
N60 mg/kg (Doxo equivalents) compared with ~12 mg/kg for Doxo
[28]. At 30 mg/kg (Doxo equivalents) no clinical signs other than
peripheral neuropathy and motor disturbances were observed in 25%
of mice which developed as a delayed toxicity following intravenous
administration of the drug [28]. In our study with Aldoxo at a three-
times higher dose of Doxo (18 mg/kg of Doxo-equivalents versus 6
mg/kg of Doxo), we did not observe any signs of neurotoxicity
marked by motor disturbances and/or imbalance. Although, Aldoxo
administered at 24 mg/kg (18 mg/kg Doxo-equivalents) was
significantly better tolerated than Doxo at 6 mg/kg, we observed
that following the last intravenous administration of Aldoxo, mice
rapidly developed morbid condition which was marked by rapid
weight loss, impaired mobility, decreased food intake, and signs of
lethargy. We do not know yet the underlying cause of this worsening
condition, but it might be a result of cumulative Aldoxo cytotoxicity,
which is still much less pronounced and develops much later than
with Doxo treatment.
Albumin is the most abundant plasma protein and is emerging as a
versatile carrier for targeting anti-tumor drugs [28]. Solid tumors
accumulate albumin due to their unique pathophysiological
characteristics, such as high metabolic turnover, extensive angiogen-
esis, defective vascular architecture, and impaired lymphatic drainage
[29,30]. While the systemic delivery of many drugs for brain tumortherapy is seriously hampered by poor drug delivery to the brain, the
role of albumin in allowing penetration of drugs through the blood
brain-tumor barrier is intriguing. Our results are consistent with an
earlier report showing that glioblastoma patients accumulated
fluorescently-labeled albumin selectively into the brain tumors and
not in the normal brain [31].
In preclinical studies, Aldoxo has shown superior anticancer efficacy
over Doxo in a number of murine xenograft models including renal cell
carcinoma, breast carcinoma, ovarian carcinoma, and small cell lung
cancer, and in an orthotopic pancreatic carcinoma model [17].
Complete remissions were achieved with Aldoxo in the renal cell
carcinoma and breast carcinoma xenograft models in nudemice [16]. In
a phase 1 study, Aldoxo showed a good safety profile and favorable
responses in patients with solid tumors such as breast cancer, small cell
lung cancer and sarcoma [20]. A potential advantage of Aldoxo is its
favorable pharmacokinetics for a long circulating drug delivery system,
such as a small volume of distribution, a high-plasma area under the
concentration-time curve, and low clearance compared withDoxo [26].
The doses of Aldoxo used in our study (24mg/kg per week or 18mg/kg
per weekDoxo-equivalents) are clinically achievable (72mg/m2 Aldoxo
or 54 mg/m2 Doxo-equivalents) and are far below the well-tolerated
dose of 200 mg/m2 (150 mg/m2 Doxo-equivalents) administered in
the phase 1 clinical trial without manifestation of drug-related side
effects [20]. This Doxo equivalent dose of Aldoxo is 2 to 2.5 times
higher than the clinically used Doxo dose of 60 to 75 mg/m2, which
often results in moderate to severe side effects.
As a result of our preclinical study, Aldoxo has emerged as a
promising clinical candidate for the treatment of brain tumors because
of its selective accumulation and prolonged retention in brain tumor
tissue and its potent antitumor activity against human GBM cells.
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